Advances in Graves' Disease

Advances in Graves' Disease

1Department of Endocrinology and Nutrition, Clinica Universidad de Navarra, 36 Pio XII Avenue, 31080 Pamplona, Spain 2Endocrine Unit, Evgenidion-Hospital, University of Athens, 11528 Athens, Greece 3Department of Medicine, C2 Link, University Hospital of Wales, Cardiff CF14 4XN, UK 4Division of Endocrinology and Metabolism, Mount Sinai School of Medicine, James J. Peters VA Medical Center, New ...

Anticardiolipin Antibodies and Immunoglobulin M and A in Graves’ Disease

Background: Graves’ disease is an autoimmune disease, characterized by the presence of antibodies directed to TSH receptor or nearby regions as well as antibodies to double strands DNA (dsDNA) anticardiolipin and nuclear antibodies. This study evaluated anticardiolipin and rheumatoid factor, such as IgA and IgM antibodies in patients with Graves’ disease. Patients and methods: Anticardiolipin a...

[Graves' disease].

Microchimerism in Graves' Disease

Microchimerism is the presence of cells from one individual in another genetically distinct individual. Pregnancy is the main cause of natural microchimerism through transplacental bidirectional cell trafficking between mother and fetus. The consequences of pregnancy-related microchimerism are under active investigation. However, many authors have suggested a close relationship linking fetal mi...

Graves' Disease.

Graves’ disease was first recognized in the 19th century as a syndrome comprising an enlarged and overactive thyroid gland, an accelerated heart rate, and ocular abnormalities (Fig. 1). Critical for our current understanding of this disease was the discovery of its autoimmune basis, which results from complex interactions between genetic and environmental factors.1,2 Graves’ disease has adverse...